Slidell Doctor Sentenced For $6.6 Million In Health Care Fraud

Why It Matters

The enforcement action underscores heightened DOJ focus on Medicare abuse and signals stricter scrutiny of tele‑medicine billing practices, protecting taxpayer dollars and patient safety.

Key Takeaways

• Doctor billed Medicare $6.6 million for unnecessary genetic tests.
• Fraud generated $2 million in Medicare reimbursements.
• Sentenced to three years probation, home confinement first year.
• Ordered to repay $2.04 million plus $106,757 forfeiture.
• DOJ’s new National Fraud Enforcement Division highlighted case.

Pulse Analysis

The sentencing of Dr. Robert Tassin illustrates how fraudulent billing can infiltrate even emerging tele‑medicine models. By signing orders for cancer‑genetic (CGx) tests without ever examining patients, Tassin leveraged a $30 per‑order fee structure to fabricate over $6.6 million in claims, of which Medicare paid more than $2 million. This case highlights the vulnerability of Medicare’s fee‑for‑service framework to exploitation when oversight relies heavily on provider‑submitted documentation rather than direct clinical verification.

Beyond the individual misconduct, the case arrives as the Department of Justice launches its National Fraud Enforcement Division, a dedicated unit aimed at curbing waste, fraud, and abuse across federal benefit programs. The division’s involvement signals a strategic shift toward coordinated, high‑visibility prosecutions of health‑care fraud, especially in areas like tele‑health where rapid adoption outpaced regulatory controls. The DOJ’s partnership with the HHS Office of Inspector General reflects a whole‑of‑government approach, reinforcing the message that fraudulent claims—whether for advanced genetic testing or routine services—will be aggressively pursued.

For health‑care providers, the ruling serves as a stark reminder to strengthen compliance programs, verify medical necessity, and maintain transparent documentation. The $2.04 million restitution and probation terms also demonstrate that financial penalties are paired with personal sanctions, deterring future misconduct. As Medicare continues to expand coverage for innovative diagnostics, stakeholders must balance access with rigorous oversight to safeguard both patient outcomes and the integrity of federal health‑care spending.